Xeljanz XR · DIN 02470608 · 11 mg · extended release tablet
Limited Use, Reason for Use code 565 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 565 required
Write on scriptReason for Use code 565 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 565
Reason for Use code 565
For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:
A. i) Methotrexate (20mg/week) for at least 3 months, AND
ii) leflunomide (20mg/day) for at least 3 months, in addition to
iii) an adequate trial of at least one combination of DMARDs for 3 months; OR
B. i) Methotrexate (20mg/week) for at least 3 months, AND
ii) leflunomide in combination with methotrexate for at least 3 months; OR
C. i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)
Maintenance/Renewal:
After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.
For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.
Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.
The recommended dosing regimen is 11mg once daily.
Coverage limit:
LU Authorization Period: 1 year
1 brand, same coverage
Xeljanz XR · DIN 02470608
Manufacturer: Pfizer Canada Inc.; listing date 2019-08-30
Health Canada: Marketed since 2018-03-29 · brand XELJANZ XR · ATC L04AF01 TOFACITINIB · form Tablet (extended-release) · route Oral · ingredients TOFACITINIB (TOFACITINIB CITRATE) 11 MG · company Pfizer canada ulc · schedule Prescription
Ministry pays: $27.2507 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02470608)
Source record
DIN 02470608: Xeljanz XR
Raw flags: sec12=Y, sec3=Y
Item: 923600015; group id 1045; item number 2400; lccId 00320; manufacturer id PFI
Source form: ER Tab; strength: 11mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $49.5467; ministry $27.2507
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02470608
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95960
Interchangeable products
Taro-Tofacitinib XR · DIN 02553988 · $27.2507
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02470608
Shortage record checked October 6, 2026